Detalhe da pesquisa
1.
Acquired Resistance to KRASG12C Inhibition in Cancer.
N Engl J Med
; 384(25): 2382-2393, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161704
2.
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
N Engl J Med
; 383(9): 825-835, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32846061
3.
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Lancet Oncol
; 22(7): 959-969, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34118197
4.
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
Oncologist
; 25(1): e39-e47, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31604903
5.
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Thyroid
; 34(1): 26-40, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38009200
6.
Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.
J Thorac Oncol
; 17(6): 768-778, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35183775
7.
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study.
JTO Clin Res Rep
; 3(12): 100427, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36426286
8.
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Cancer Discov
; 12(7): 1676-1689, 2022 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35404393
9.
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
J Thorac Oncol
; 17(3): 411-422, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34801749
10.
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations.
Lung Cancer (Auckl)
; 12: 61-65, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34285620
11.
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
Lung Cancer
; 158: 126-136, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175504
12.
Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
Transl Oncol
; 14(11): 101191, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34365220
13.
A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.
JTO Clin Res Rep
; 2(1): 100116, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34589977
14.
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
J Thorac Oncol
; 16(5): 740-763, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33338652
15.
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
Lung Cancer
; 157: 147-155, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34049720
16.
Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing.
JTO Clin Res Rep
; 2(2): 100132, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34589990
17.
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
Cancer Discov
; 11(7): 1688-1699, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33632775
18.
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers.
JTO Clin Res Rep
; 2(7): 100187, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34590036
19.
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
J Clin Oncol
; 39(25): 2791-2802, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34077268
20.
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Lancet Diabetes Endocrinol
; 9(8): 491-501, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34118198